Manager, Business Development
Jerry- Full Time
- Mid-level (3 to 4 years), Senior (5 to 8 years)
Employment Type: Full-time
Asimov is seeking a proactive and results-driven Business Development Manager for Europe to join our rapidly growing Commercial Team. This senior individual contributor role focuses on driving new business within the territory, nurturing relationships with existing partners, and increasing market awareness of Asimov. The successful candidate will demonstrate leadership, autonomy, and strategic ownership, collaborating across teams to achieve collective goals and make an immediate impact on Asimov’s commercial growth and strategy.
Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We are developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics. We are fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved through diverse perspectives and collaborative innovation.
Synthetic biology solutions for biopharmaceuticals
Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their products include cloud-based software that allows clients in the biopharmaceutical industry to design, simulate, and optimize genetic systems. Additionally, they offer engineered GMP host cells that are used for therapeutic applications. Asimov distinguishes itself from competitors by guaranteeing high titer cell lines for monoclonal antibodies with a promise of '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.